Stockreport

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Clovis Oncology, Inc.  (CLVS) 
Last clovis oncology, inc. earnings: 2/24 04:05 pm Check Earnings Report
PDF Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022Res [Read more]